# A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

> **NCT04547127** · PHASE2 · COMPLETED · sponsor: **Instituto Grifols, S.A.** · enrollment: 200 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Convalescent anti-SARS-CoV-2 MBT Plasma
- **DRUG:** Standard Medical Treatment

## Key facts

- **NCT ID:** NCT04547127
- **Lead sponsor:** Instituto Grifols, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-29
- **Primary completion:** 2021-02-04
- **Final completion:** 2021-02-04
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2021-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04547127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04547127, "A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04547127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*